Price Alert

TriSalus Life Sciences In... (TLSI)

NASDAQ: TLSI · Real-Time Price · USD

4.30

0.42 (10.82%)

At close: Aug 15, 2025, 11:56 AM

TriSalus Life Sciences Statistics

Share Statistics

TriSalus Life Sciences has 37.98M shares outstanding. The number of shares has increased by 29.56% in one year.

Shares Outstanding	37.98M
Shares Change (YoY)	29.56%
Shares Change (QoQ)	24.54%
Owned by Institutions (%)	10.33%
Shares Floating	15.02M
Failed to Deliver (FTD) Shares	4,709
FTD / Avg. Volume	5.59%

Short Selling Information

The latest short interest is 605.28K, so 1.59% of the outstanding shares have been sold short.

Short Interest	605.28K
Short % of Shares Out	1.59%
Short % of Float	2.46%
Short Ratio (days to cover)	15.15

Valuation Ratios

The PE ratio is -4 and the forward PE ratio is -23.29. TriSalus Life Sciences's PEG ratio is 0.09.

PE Ratio	-4
Forward PE	-23.29
PS Ratio	4.51
Forward PS	1.9
PB Ratio	-5.13
P/FCF Ratio	-3.22
PEG Ratio	0.09

Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for TriSalus Life Sciences.

EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 2.02, with a Debt / Equity ratio of -0.91.

Current Ratio	2.02
Quick Ratio	1.63
Debt / Equity	-0.91
Debt / EBITDA	-0.65
Debt / FCF	-0.57
Interest Coverage	-11.7

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity	n/a
Return on Assets	n/a
Return on Invested Capital	n/a
Revenue Per Employee	$267.55K
Profits Per Employee	$-302.12K
Employee Count	110
Asset Turnover	1.23
Inventory Turnover	1.01

Taxes

Income Tax	6K
Effective Tax Rate	-0.02%

Stock Price Statistics

The stock price has increased by -39.55% in the last 52 weeks. The beta is 0.48, so TriSalus Life Sciences's price volatility has been higher than the market average.

Beta	0.48
52-Week Price Change	-39.55%
50-Day Moving Average	4.91
200-Day Moving Average	4.95
Relative Strength Index (RSI)	34.89
Average Volume (20 Days)	84,198

Income Statement

In the last 12 months, TriSalus Life Sciences had revenue of 29.43M and earned -33.23M in profits. Earnings per share was -1.25.

Revenue	29.43M
Gross Profit	25.33M
Operating Income	-36.16M
Net Income	-33.23M
EBITDA	-36.16M
EBIT	-33.13M
Earnings Per Share (EPS)	-1.25

Full Income Statement

Balance Sheet

The company has 8.53M in cash and 23.63M in debt, giving a net cash position of -15.1M.

Cash & Cash Equivalents	8.53M
Total Debt	23.63M
Net Cash	-15.1M
Retained Earnings	-279.55M
Total Assets	28.63M
Working Capital	13.34M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -40.84M and capital expenditures -345K, giving a free cash flow of -41.19M.

Operating Cash Flow	-40.84M
Capital Expenditures	-345K
Free Cash Flow	-41.19M
FCF Per Share	-1.55

Full Cash Flow Statement

Margins

Gross margin is 86.06%, with operating and profit margins of -122.88% and -112.92%.

Gross Margin	86.06%
Operating Margin	-122.88%
Pretax Margin	-102.07%
Profit Margin	-112.92%
EBITDA Margin	-122.88%
EBIT Margin	-122.88%
FCF Margin	-139.95%

Dividends & Yields

TLSI does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Payout Ratio	n/a
Earnings Yield	n/a
FCF Yield	n/a

Dividend Details

Analyst Forecast

The average price target for TLSI is $11, which is 211.6% higher than the current price. The consensus rating is "Buy".

Price Target	$11
Price Target Difference	211.6%
Analyst Consensus	Buy
Analyst Count	5

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Scores

Altman Z-Score	-13.69
Piotroski F-Score	2